| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S11060-008-9676-4 |
| P698 | PubMed publication ID | 18712279 |
| P2093 | author name string | Giovanni Marini | |
| Edda Simoncini | |||
| Salvatore Grisanti | |||
| Vittorio Ferrari | |||
| Lucia Vassalli | |||
| Francesca Valcamonico | |||
| Vito Amoroso | |||
| Giovanni Rangoni | |||
| Patrizia Marpicati | |||
| P2860 | cites work | Sorafenib in advanced clear-cell renal-cell carcinoma | Q28282767 |
| BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis | Q29617585 | ||
| Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma | Q34293726 | ||
| Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis | Q34295286 | ||
| Renal-cell carcinoma | Q34394356 | ||
| Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm | Q34632917 | ||
| Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors | Q36807146 | ||
| Protein kinase inhibitors in the treatment of renal cell carcinoma: sorafenib | Q36860180 | ||
| Renal cell carcinoma: new developments in molecular biology and potential for targeted therapies | Q37047728 | ||
| Sunitinib relieves renal cell carcinoma spinal cord compression. | Q51775532 | ||
| Complete cerebral response with sunitinib for metastatic renal cell carcinoma | Q80735856 | ||
| Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma | Q83195713 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 47-50 | |
| P577 | publication date | 2008-08-19 | |
| P1433 | published in | Journal of Neuro-Oncology | Q15752119 |
| P1476 | title | Long-lasting successful cerebral response with sorafenib in advanced renal cell carcinoma | |
| P478 | volume | 91 |
| Q37809571 | A new patient-focused approach to the treatment of metastatic renal cell carcinoma: establishing customized treatment options |
| Q48167222 | A phase I trial of concurrent sorafenib and stereotactic radiosurgery for patients with brain metastases. |
| Q37870216 | Combining temozolomide with other antitumor drugs and target-based agents in the treatment of brain metastases: an unending quest or chasing a chimera? |
| Q33685045 | Extracerebral metastases determine the outcome of patients with brain metastases from renal cell carcinoma. |
| Q41808513 | Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters |
| Q38631975 | Oral Targeted Therapies and Central Nervous System (CNS) Metastases |
| Q37614576 | Sorafenib reveals efficacy in sequential treatment of metastatic renal cell cancer |
| Q24642195 | Successful treatment of a brain-metastasized renal cell carcinoma |
| Q34088696 | Targeted therapies in renal cell cancer: recent developments in imaging |
| Q54633298 | The plasma and cerebrospinal fluid pharmacokinetics of sorafenib after intravenous administration in non-human primates. |
| Q58023833 | Therapie von Hirnmetastasen und Meningeosis neoplastica |
| Q45100164 | Treatment of brain metastases from renal cell cancer |
| Q48230634 | Treatment strategy for metastatic brain tumors from renal cell carcinoma: selection of gamma knife surgery or craniotomy for control of growth and peritumoral edema |
| Q35577914 | Tyrosine kinase inhibitors ameliorate autoimmune encephalomyelitis in a mouse model of multiple sclerosis |
| Q84356743 | [Surgical treatment for renal cancer metastases] |
Search more.